Nuzide M Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, promoting better glucose uptake by muscle tissues. The synergistic action of these two agents helps achieve optimal blood glucose regulation in patients inadequately controlled by diet and exercise alone. Nuzide M is particularly beneficial for patients with insulin resistance and impaired beta-cell function. It should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of blood glucose levels and renal function is essential during therapy to prevent hypoglycemia and lactic acidosis, a rare but serious adverse effect linked to Metformin. Contraindications include severe renal impairment, diabetic ketoacidosis, and hypersensitivity to either component. Nuzide M Tablet should be prescribed under medical supervision, with dose adjustments based on therapeutic response and patient tolerance, to ensure safe and effective diabetes management.